

Supporting Information

Regioselective manipulation of GlcNAc provides allosamine, lividosamine, and related compounds

Ji Zhang, Niek N. H. M. Eisink, Martin D. Witte,* and Adriaan J. Minnaard*


Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands

Corresponding Authors:

Prof. Dr. Ir. Adriaan J. Minnaard – a.j.minnaard@rug.nl


Prof. Dr. Martin Witte – m.d.witte@rug.nl.

Spectroscopic data	S3
X-ray crystallography:	S83
<i>Literature</i>	S86




Scheme S1. Initial study to prepare D-allosamine starting from methyl- α -GlcNAc

4-(benzylcarbamoyl)-4-hydroxy-2-(hydroxymethyl)-6-isopropoxytetrahydro-2H-pyran-3-yl benzoate (22a and 22b)






(2S,3R,4S,5R,6R)-3-acetamido-N-benzyl-4,5-dihydroxy-6-(hydroxymethyl)-2-isopropoxytetrahydro-2H-pyran-4-carboxamide (23)





Spectroscopic data



Methyl 2-acetamido-2-deoxy- α -D-glucopyranoside (2)











Methyl 2-acetamido-2-deoxy- α -D-glucopyran-3-ulose (3)













Methyl 2-acetamido-2-deoxy- α -D-allopyranoside (4)










Isopropyl 2-acetamido-2-deoxy- α -D-glucopyranoside (6)






JZG071#6-19 cd3od_CARBON_APT_20170522100355









Isopropyl 2-acetamido-2-deoxy- α -D-glucopyran-3-uloside (7)










Isopropyl 2-acetamido-2-deoxy- α -D-allopyranoside (8)





JZG078cd3od_CARBON_APT_20170515120042









Isopropyl 2-acetamido-2-deoxy-β-D-glucopyran-3-uloside (25).











Isopropyl 2-acetamido-2-deoxy- β -D-allopyranoside (26).




A mixture of Gluco and allo-configured products after reduction with NaBH_4 .


JZG225_20181010174414



20181010174046








Isopropyl 2-acetamido-2-deoxy- β -D-allopyranoside












NL:
1.41E8
JZG225#2-15 RT:
0.01-0.37 AV: 14 T:
FTMS + p ESI Full
ms [120.00-550.00]



NL:
8.70E5
C₁₁H₂₁NO₆Na:
C₁₁H₂₁N₁O₆Na₁
pa Chrg 1






NL:
1.41E8
JZG225#2-15 RT:
0.01-0.37 AV: 14 T:
FTMS + p ESI Full
ms [120.00-550.00]




NL:
8.70E5
C₁₁H₂₁NO₆Na:
C₁₁H₂₁N₁O₆Na₁
pa Chrg 1



Isopropyl 2-acetamido-2-deoxy-β-D-glucopyranoside









D-Allosamine (5)











Benzyl 2-acetamido-2-deoxy- α -D-glucopyranoside (9)













Benzyl 2-acetamido-2-deoxy- α -D-glucopyran-3-uloside (10)









Benzyl 2-acetamido-2-deoxy- α -D-allopyranoside (11)








NL:
1.50E7
JZG_081#6-21
RT: 0.13-0.55 AV:
16 T: FTMS + p ESI
Full ms
[120.00-550.00]



NL:
8.33E5
C₁₅H₂₂NO₆:
C₁₅H₂₂N₁O₆
pa Chrg 1





NL:
1.11E7
JZG_081#6-21
RT: 0.13-0.55 AV:
16 T: FTMS + p ESI
Full ms
[120.00-550.00]

NL:
8.33E5
C₁₅H₂₂NO₆:
C₁₅H₂₂N₁O₆
pa Chrg 1

N-acetyl D-allosamine (12)




JZG082_d2o_CARBON_APT_20170520130356






NL:
6.48E6
JZG_082#9-20
RT: 0.20-0.51 AV:
12 T: FTMS + p ESI
Full ms
[180.00-550.00]


NL:
8.99E5
C₈H₁₅NO₆Na:
C₈H₁₅N₁O₆Na₁
pa Chrg 1



***N*-((2*S*,3*R*,5*S*,6*R*,*Z*)-5-hydroxy-6-(hydroxymethyl)-2-isopropoxy-4-(2-tosylhydrazono)tetrahydro-2*H*-pyran-3-yl)acetamide (13)**









NL:
3.89E6
JZG092#7-22 RT:
0.15-0.57 AV: 16
T: FTMS + p ESI
Full ms
[350.00-750.00]

NL:
7.58E5
C₁₈H₂₈N₃O₇S:
C₁₈H₂₈N₃O₇S₁
pa Chrg 1






NL:
7.34E4
JZG092#7-22 RT:
0.15-0.57 AV: 16
T: FTMS + p ESI
Full ms
[350.00-750.00]



NL:
7.58E5
C₁₈H₂₈N₃O₇S:
C₁₈H₂₈N₃O₇S₁
pa Chrg 1




***N*-((2*S*,3*R*,4*S*,5*S*,6*R*)-5-hydroxy-6-(hydroxymethyl)-2-isopropoxy-4-(2-tosylhydrazinyl)tetrahydro-2*H*-pyran-3-yl)acetamide (14)**










[illegible]

JZG166cd3od_APT_20180320175155
STANDARD FLUORINE PARAMETERS









NL:
2.45E6
JZG166#6-21 RT:
0.12-0.54 AV: 16
T: FTMS + p ESI
Full ms
[180.00-550.00]

NL:
8.72E5
C₁₁H₂₂NO₅
C₁₁H₂₂N₁O₅
pa Chrg 1


D-lividosamin (16)











^1H NMR of D-lividosamine hydrochloride after D_2O









***E/Z*-Isopropyl 2-acetamido-2-deoxy-3-*O*-methyloxime- α -D-ribo-hexapyranoside (17)**





JZG_097#6-32.cd3od_CARBONAPT_20170717180659







Isopropyl 2-acetamido-3-amino-2,3-dideoxy- α -D-allopyranoside (18)




JZG098_c88od_CARBON_APT_20170731174702




NL:
5.23E7
JZG098#6-20 RT:
0.13-0.52 AV: 15
T: FTMS + p ESI
Full ms
[120.00-550.00]


NL:
8.69E5
C₁₁H₂₃N₂O₅:
C₁₁H₂₃N₂O₅
pa Chrg 1




Isopropyl 2,3-diamino-2,3-dideoxy- α -D-allopyranoside (19)







JZG14_20180503005008
20180502200908







JZG114_20180502234849
20180502200836








(3aR,4S,6R,7S,7aS)-2-(4-bromophenyl)-6-(hydroxymethyl)-4-isopropoxy-3,3a,4,6,7,7a-hexahydropyrano[3,4-d]imidazol-7-ol (20)












(4*S*,6*R*,7*S*)-2-(4-bromophenyl)-6-(hydroxymethyl)-4-isopropoxy-3,4,6,7-tetrahydropyrano [3, 4-*d*] imidazol-7-ol (21)












(2*S*,3*R*,4*S*,5*R*,6*R*)-3-acetamido-4-(benzylcarbamoyl)-5-hydroxy-6-(hydroxymethyl)-2-isopropoxytetrahydro-2*H*-pyran-4-yl benzoate (22a)












(2R,3R,4S,5R,6S)-5-acetamido-4-(benzylcarbamoyl)-4-hydroxy-2-(hydroxymethyl)-6-isopropoxytetrahydro-2H-pyran-3-yl benzoate (22b)












(2*S*,3*R*,4*S*,5*R*,6*R*)-3-acetamido-*N*-benzyl-4,5-dihydroxy-6-(hydroxymethyl)-2-isopropoxytetrahydro-2*H*-pyran-4-carboxamide (23)












Tert-butyl (Z)-2-((2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-2-isopropoxytetrahydro-4H-pyran-4-ylidene)hydrazine-1-carboxylate (24)










NL:
2.92E7
JZG164#3-15 RT:
0.04-0.37 AV: 13 T:
FTMS + p ESI Full
ms [120.00-550.00]



NL:
8.16E5
 $C_{16}H_{29}N_3O_7Na$:
 $C_{16}H_{29}N_3O_7Na_1$
pa Chrg 1

X-ray crystallography:




Figure S1. Molecular structure of compound **24**·CH₃OH, showing 50% probability ellipsoids. Hydrogen atoms are omitted for clarity.

A single crystal of compound **24** was mounted on top of a cryoloop and transferred into the cold nitrogen stream (100 K) of a Bruker-AXS D8 Venture diffractometer. Data collection and reduction was done using the Bruker software suite APEX3.¹ The final unit cell was obtained from the xyz centroids of 9994 reflections after integration. A multiscan absorption correction was applied, based on the intensities of symmetry-related reflections measured at different angular settings (*SADABS*). The structures were solved by direct methods using *SHELXT*³ and refinement of the structure was performed using *SHLELXL*.⁴ The hydrogen atoms were generated by geometrical considerations, constrained to idealized geometries and allowed to ride on their carrier atoms with an isotropic displacement parameter related to the equivalent displacement parameter of their carrier atoms. Crystal data and details on data collection and refinement are presented in Table S1

Table S1. Crystallographic data for **24**

chem formula	C17 H33 N3 O8
M _r	407.46
cryst syst	Monoclinic
color, habit	Colourless, block
size (mm)	0.52 x 0.27 x 0.15
space group	P 21
a (Å)	10.2358(7)
b (Å)	8.6625(6)
c (Å)	12.4764(10)
α, deg	90
β, deg	90.477(2)

γ , deg	90
V ($\text{\AA}^3$)	1106.21(14)
Z	2
ρ_{calc} , $\text{g}\cdot\text{cm}^{-3}$	1.450
$\mu(\text{Mo K}\alpha)$, cm^{-1}	0.097
$F(000)$	440
temp (K)	100(2)
θ range (deg)	3.081 – 28.329
data collected (h,k,l)	-13:13, -11:11, -16:16
no. of rflns collected	39951
no. of indepndt rflns	5506
observed rflns	4867 ($F_o \geq 2 \sigma(F_o)$)
$R(F)$ (%)	3.92
$wR(F^2)$ (%)	9.08
GooF	1.042
Weighting a,b	0.0422, 0.3097
params refined	266
restraints	1
min, max resid dens	-0.248, 0.409




Figure S2. Molecular structure of **4** with two molecules per unit cell, showing 50% probability ellipsoids. Hydrogen atoms are omitted for clarity.

A single crystal of compound **4** was mounted on top of a cryoloop and transferred into the cold nitrogen stream (100 K) of a Bruker-AXS D8 Venture diffractometer. Data collection and reduction was done using the Bruker software suite APEX3.² The final unit cell was obtained from the xyz centroids of 9804 reflections after integration. A

multiscan absorption correction was applied, based on the intensities of symmetry-related reflections measured at different angular settings (*SADABS*). The structures were solved using *SHELXT*³ and refinement of the structure was performed using *SHELXL*.⁴ The hydrogen atoms were generated by geometrical considerations, constrained to idealized geometries and allowed to ride on their carrier atoms with an isotropic displacement parameter related to the equivalent displacement parameter of their carrier atoms. The absolute configuration of the model was chosen based on anomalous dispersion effects, and refinement of Flack's parameter converged to 0.03(3). Crystal data and details on data collection and refinement are presented in Table S2

Table S2. Crystallographic data for **4**

chem formula	C ₉ H ₁₇ N O ₆
M _r	235.23
cryst syst	orthorhombic
color, habit	colorless, block
size (mm)	0.40 x 0.25 x 0.12
space group	P 21 21 21
a (Å)	9.6845(2)
b (Å)	11.1866(2)
c (Å)	20.2699(5)
V (Å ³)	2195.97(8)
Z	8
ρ_{calc} , g.cm ⁻³	1.423
$\mu(\text{Mo K}\alpha)$, cm ⁻¹	1.026
F(000)	1008
temp (K)	100(2)
θ range (deg)	4.362 – 74.583
data collected (h,k,l)	-12:11, -13:13, -25:25
no. of rflns collected	30369
no. of indepndt rflns	4453
observed rflns	4365 ($F_o \geq 2 \sigma(F_o)$)
R(F) (%)	2.34
wR(F ²) (%)	6.04
GooF	1.089
Weighting a,b	0.0359, 0.3176
params refined	305
restraints	0
min, max resid dens	-0.171, 0.204
Flack x	0.03(3)

Literature

- (1) Bruker, (2016). *APEX3* (v2012.4-3), *SAINT* (Version 8.18C) and *SADABS* (Version 2012/1). Bruker AXS Inc., Madison, Wisconsin, USA.
- (2) Bruker, (2016). *APEX3* (v2016.1-0), *SAINT* (Version 8.37A) and *SADABS* (Version 2014/5). Bruker AXS Inc., Madison, Wisconsin, USA.
- (3) Sheldrick, G. M. SHELXT– Integrated space-group and crystal-structure determination. *Acta Crystallographica Section A* **2015**, 71, 3-8.
- (4) Sheldrick, G. M. A short history of SHELX. *Acta Crystallographica Section A* **2008**, 64, 112-122.